3520
Z. Liu et al. / Tetrahedron Letters 51 (2010) 3518–3520
Table 3
Acknowledgments
Results of amino acid generation
This work was supported by US Public Health Service Grants DK
1) m-CPBA,CH2Cl2,
S
17420 and the National Institute of Drug Abuse DA 06284, DA
13449. We also thank Professor Richard Glass (the University of
Arizona) for useful discussions.
R
3 R2
O
R3 R
-78 oC ~ rt
2
N
HO
R1
NHCbz
3 ( ), Anti
2) I2, THF/H2O, 4d
3) Zn dust, AcOH, 70 oC
R1
NHCbz
4 ( ), Anti
Supplementary data
Supplementary data associated with this article can be found, in
Entry
R1, R2, R3
Anti/syn
Yieldsa
4d
4e
4g
4h
COOEt, H, H
H, H, Me
H, H, COOMe
H, H, COOEt
n/a
78
76
82
83
10:1b
>49:1b
>49:1b
References and notes
1. Sawyer, T. K. Peptidomimetic and Nonpeptide Drug Discovery: Impact of
Structure-Based Drug Design. In Veerapandian, P., Ed.; Structure Based Drug
Design: Disease, Targets, Techniques and Development; Marcel Dekker: New
York, 1997; p 559.
a
Isolated yield of total isomers.
Determined by 1H NMR.
b
2. Noren, C. J.; Anthonycahill, S. J.; Griffith, M. C.; Schultz, P. G. Science 1989, 244,
182.
3. Saks, M. E. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2125.
4. Hruby, V. J. Nat. Rev. Drug Disc. 2002, 1, 847.
establish a hydrogen bond with the a-amino group, forming a sec-
ond six-membered ring to further stabilize the transition state (A0
in Fig. 1).
5. Marx, V. Chem. Eng. News 2005, 83, 17.
The final step of converting the thioamide into the carboxylic
acid is always a challenge, especially when our compounds carry
the ester functional groups and two acidic a-protons at two stere-
6. Sehgal, A. Genet. Eng. Biotechnol. News 2007, 27, 12.
7. Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. Nat. Rev. Drug Disc.
2009, 8, 69.
8. Rutjes, F. P. J. T.; Wolf, L. B.; Schoemaker, H. E. J. Chem. Soc., Perkin Trans. 1 2000,
4197.
9. Ueki, T.; Morimoto, Y.; Kinoshita, T. Chem. Commun. (Camb) 2001, 1820.
10. Dennis, R. L.; Plant, W. J.; Skinner, C. G.; Sutherland, G. L.; Shive, W. J. Am. Chem.
Soc. 1955, 77, 2362.
11. Katagiri, K.; Tori, K.; Kimura, Y.; Yoshida, T.; Nagasaki, T.; Minato, H. J. Med.
Chem. 1967, 10, 1149.
12. Kubel, B.; Hofle, G.; Steglich, W. Angew. Chem., Int. Ed. Engl. 1975, 14, 58.
13. Bartlett, P. A.; Barstow, J. F. J. Org. Chem. 1982, 47, 3933.
14. Kazmaier, U. Angew. Chem., Int. Ed. Engl. 1994, 33, 998.
15. Kazmaier, U.; Krebs, A. Angew. Chem., Int. Ed. Engl. 1995, 34, 2012.
16. Qu, H.; Gu, X.; Min, B. J.; Liu, Z.; Hruby, V. J. Org. Lett. 2006, 8, 4215.
17. Qu, H.; Gu, X.; Liu, Z.; Min, B. J.; Hruby, V. J. Org. Lett. 2007, 9, 3997.
18. Liu, Z.; Qu, H.; Gu, X.; Min, B. J.; Nichol, G. S.; Nyberg, J.; Hruby, V. J. Org. Lett.
2008, 10, 4105.
ogenic centers. The previously reported one-pot alkylation–reduc-
tion–oxidation method was found not to be appropriate due to the
reactivity of the b-ester functional group. Therefore, an oxidation–
iodolactonization–reduction method was used instead. The thio-
amides 3 were first converted to the amides23 and used without
purification to form the iodolactones,24 which were subjected to
a reductive elimination reaction with zinc to open the lactone ring
and form both the carboxylic acid and the terminal double bond
simultaneously.25 Results are presented in Table 3, showing that
little or no epimerization happened during the reaction.
In conclusion, we have disclosed a significantly improved
thio–Claisen rearrangement method for preparing novel anti-
19. Tamaru, Y.; Mizutani, M.; Furukawa, Y.; Kitao, O.; Yoshida, Z. Tetrahedron Lett.
1982, 23, 5319.
b-functionalized
c,d-unsaturated amino acids. The mild reaction
20. Cava, M. P.; Levinson, M. I. Tetrahedron 1985, 41, 5061.
21. Tamaru, Y.; Furukawa, Y.; Mizutani, M.; Kitao, O.; Yoshida, Z. J. Org. Chem. 1983,
48, 3631.
22. He, S. W.; Kozmin, S. A.; Rawal, V. H. J. Am. Chem. Soc. 2000, 122, 190.
23. Kochhar, K. S.; Cottrell, D. A.; Pinnick, H. W. Tetrahedron Lett. 1983, 24, 1323.
24. Tamaru, Y.; Mizutani, M.; Furukawa, Y.; Kawamura, S. I.; Yoshida, Z. I.; Yanagi,
K.; Minobe, M. J. Am. Chem. Soc. 1984, 106, 1079.
conditions not only offered good to excellent anti/syn selectivities
in high yield but also make it possible to greatly expand the func-
tional group availability in these amino acids. Further investigation
of the enantioselective synthesis of these novel amino acids, the
scope of this synthetic methodology, and the applications of these
synthesized novel amino acids to drug design is in progress.
25. Metz, P.; Hungerhoff, B. J. Org. Chem. 1997, 62, 4442.